Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
In previous phase I/II oncology trials for drug combinations, a number of methods have been studied to determine the dose combination for the next cohort. However, there is a risk that trial durations will be unfeasibly long if methods for evaluating safety and efficacy are based on the best overall...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-09-01
|
| Series: | Contemporary Clinical Trials Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865416301314 |